Journal of Cancer Science & Therapy (JCST) brings articles in all areas related to Cancer on monthly basis. JCST welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately 15 days after acceptance. Journal has received a major response of research and review articles in the recent volumes and issue releases. Recent trends in reserach and development of Cancer treatment and survival reports are almost a basic need for further research.
As a member of Publisher International Linking Association, PILA, HILARIS SRL JCST follows the Creative Commons Attribution License and Scholars Open Access publishing policies.Journal of Cancer Science & Therapy is the Council Contributor Member for Council of Science Editors (CSE) and follows the CSE’s slogan ‘Education, Ethics, and Evidence for Editors’.
Submit manuscript online at https://www.scholarscentral.org/submissions/cancer-science-therapy.html or send as an e-mail attachment to the Editorial Office at editor@hilarisjournal.com
A manuscript number will be e-mailed to the corresponding author within 72 hours.
Aim & Scope:
The Journal of Cancer Science and Therapy is the best platform for advancements of oncology research. The journal has eminent scientists in the field of oncology across the globe. Editorial broad members have dedicated commitment for peer review process. Journal publishes original research articles, commentary, case reports as well as review articles in major disciplines of oncology, anti-cancer drug, cancer therapies, lung tumour, sarcoma cancer and lymph node cancer.
Peer review process:
Journal of Cancer Science and Therapy follows Double-blind peer review. In this review process reviewers are unaware of the identity of the authors, and authors are also unaware of the identity of reviewers. There are at least two or more reviewers for the total number of articles in each issue.
Other comments:
Journal of Cancer Science and Therapy mainly focuses on oncology advancements. The journal serving the scientific community from last twelve years and updating the best oncology scientific reports.
Publication Ethics and Malpractice Statement
The Executive Editor or/and Editor-in-Chief of Cancer Science & Therapy is responsible for deciding which of the articles submitted to the journal should be published in current volume of the journal. He may be guided by the policies of the journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism.
An editor at any time evaluate manuscripts for their intellectual content without regard to the nature of the authors or the host institution including race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.
The editor must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author.
When genuine errors in published work are pointed out by readers, authors, or members of editorial board, which do not render the work invalid, a correction (or erratum) will be published as soon as possible. The online version of the paper may be corrected with a date of correction and a link to the printed erratum. If the error renders the work or substantial parts of it invalid, the process of retraction can be initiated. In such case, the retraction communication with explanations as to the reason for retraction will be published as soon as possible. Consequently, the message about retraction will be indicated on article page and in pdf version of retracted article.
If serious concerns are raised by readers, reviewers, or others, about the conduct, validity, or reporting of academic work, editor will initially contact the authors and allow them to respond to the concerns. If that response is unsatisfactory, Cancer Science & Therapy will take this to the institutional level.
Cancer Science & Therapy will respond to all allegations or suspicions of research or publication misconduct raised by readers, reviewers, or other editors. Cases of possible plagiarism or duplicate/redundant publication will be assessed by the journal. In other cases, Cancer Science & Therapy may request an investigation by the institution or other appropriate bodies (after seeking an explanation from the authors first and if that explanation is unsatisfactory).
Retracted papers will be retained online, and they will be prominently marked as a retraction in all online versions, including the PDF, for the benefit of future readers.
HILARIS SRL Policy Regarding the NIH Mandate
HILARIS SRL will support authors by posting the published version of articles by NIH grant-holders and European or UK-based biomedical or life sciences grant holders to PubMed Central immediately after publication
Article Processing Charges (APC) :
HILARIS SRL Journal of Cancer Science & Therapy is self-financed and does not receive funding from any institution/government. Hence, the Journal operates solely through processing charges we receive from the authors and some academic/corporate sponsors. The handling fee is required to meet its maintenance. Being an Open Access Journal, JCST does not collect subscription charges from readers that enjoy free online access to the articles. Authors are hence required to pay a fair handling fee for processing their articles. However, there are no submission charges. Authors are required to make payment only after their manuscript has been accepted for publication.
Regular Article Processing Charges:
The regular processing and publishing charges per an article in the journal is 2300 Euros.
Average Article prorcessing time (APT) is 55 days
Rapid Publication Service
Hilaris Publishing is offering wide range of opportunities, options and services for the prospective authors to publish their scholarly contributions.
The journal caters to the demands of the fast publication without compromising on the editorial quality including manuscript peer-review. This flexibility is being provided to ensure earliest author credibility to their respective contributions and this will also ensure timely dissemination of research outcomes for efficient integration, effective translation and reduced redundancy.
Authors have the option to choose between the standard open access publication service which takes its own course of time for complete publication process or can opt for rapid publication service wherein the article is published at the earliest date (Includes multiple subject experts commissioning for securing earliest peer-review comments). The authors can avail this flexibility based on the personal preference, funding agency guidelines or Institutional or organizational requirements.
Regardless of the option, all manuscripts undergo thorough peer-review process, editorial assessment and production process.
Fast Editorial Execution and Review Process (FEE-Review Process)
Authors who are willing to publish their articles under this mode can make a pre-payment of $99 towards express peer-review and editorial decision. First editorial decision in 3 days and final decision with review comments in 5 days from the date of submission. Galley proof generation will be done in next 2 days from acceptance or maximum 5 days (For manuscripts notified for revision by external reviewer).
Manuscripts accepted for publication will be charged regular APC.
Authors retain the copyright of their publication and the final version of the article will be published in both HTML and PDF formats as well as XML formats for transmitting to indexing databases. The editorial team of the Journal will ensure adherence to scientific publication guidelines.
The basic article processing fee or manuscript handling cost is as per the price mentioned above on the other hand it may vary based on the extensive editing, colored effects, complex equations, extra elongation of no. of pages of the article, etc.
Submission of an Article
In order to reduce delays, authors should adhere to the level, length and format of the HILARIS SRL Journals at every stage of processing right from manuscript submission to each revision stage. Submitted articles should have a 300 words summary/abstract, separate from the main text. The summary should provide a brief account of the work by clearly stating the purpose of the study and the methodology adopted, highlighting major findings briefly. The text may contain a few short subheadings of no more than 40 characters each.
Author Withdrawal Policy
From time to time after submission, an author may wish to withdraw his manuscript. An author is free to withdraw his article at no charge as long as it is withdrawn within 7 days of initial submission. Further withdrawal charges may be imposed to compensate all the efforts and expenses that are incurred in the due course of processing the article. The withdrawal charges may be around 30-80% of the regular publication charges depending on the time of withdrawal.
Formats for HILARIS SRL Contributions
HILARIS SRL accepts various formats of literary works such as research articles, reviews, abstracts, addendums, announcements, article-commentaries, book reviews, rapid communications, letters to the editor, annual meeting abstracts, conference proceedings, calendars, case-reports, corrections, discussions, meeting-reports, news, obituaries, orations, product reviews, hypotheses and analyses.
Article Preparation Guidelines
Guidelines for Research Articles
Review Articles
Commentaries
Case Study
Editorials
Clinical Images
Letters to the Editor/Concise Communications
Acknowledgement: This section includes acknowledgment of people, grant details, funds, etc.
Note: If an author fails to submit his/her work as per the above instructions, they are requested to maintain clear titles namely headings, subheading.
References:Only published or accepted manuscripts should be included in the reference list. Meetings abstracts, conference talks, or papers that have been submitted but not yet accepted should not be cited. All personal communications should be supported by a letter from the relevant authors.
HILARIS SRL uses the numbered citation (citation-sequence) method. References are listed and numbered in the order that they appear in the text. In the text, citations should be indicated by the reference number in brackets. Multiple citations within a single set of brackets should be separated by commas. When there are three or more sequential citations, they should be given as a range. Example: "... now enable biologists to simultaneously monitor the expression of thousands of genes in a single experiment [1,5-7,28]". Make sure the parts of the manuscript are in the correct order for the relevant journal before ordering the citations. Figure captions and tables should be at the end of the manuscript.
Authors are requested to provide at least one online link for each reference as following (preferably PubMed). Because all references will be linked electronically as much as possible to the papers they cite, proper formatting of the references is crucial. Please use the following style for the reference list:
Examples
Published Papers
Note: Please list the first five authors and then add "et al." if there are additional authors.
Electronic Journal Articles Entrez Programming Utilities
Books
Conferences
Tables
These should be used at a minimum and designed as simple as possible. We strongly encourage authors to submit tables as .doc format. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. Preferably, the details of the methods used in the experiments should be described in the legend instead of the text. The same data should not be presented in both table and graph form or repeated in the text. Cells can be copied from an Excel spreadsheet and pasted into a word document, but Excel files should not be embedded as objects.
Note: If the submission is in PDF format, the author is requested to retain the same in .doc format in order to aid in completion of process successfully.
FiguresThe preferred file formats for photographic images are .doc, TIFF and JPEG. If you have created images with separate components on different layers, please send us the Photoshop files.All images must be at or above intended display size, with the following image resolutions: Line Art 800 dpi, Combination (Line Art + Halftone) 600 dpi, Halftone 300 dpi. See the Image quality specifications chart for details. Image files also must be cropped as close to the actual image as possible.Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.
Figure legends: These should be typed in numerical order on a separate sheet.
Tables and Equations as Graphics
If equations cannot be encoded in MathML, submit them in TIFF or EPS format as discrete files (i.e., a file containing only the data for one equation). Only when tables cannot be encoded as XML/SGML can they be submitted as graphics. If this method is used, it is critical that the font size in all equations and tables is consistent and legible throughout all submissions.
Supplementary Information
All Supplementary Information (figures, tables and Summary diagram/, etc.) is supplied as a single PDF file, where possible. File size within the permitted limits for Supplementary Information. Images should be a maximum size of 640 x 480 pixels (9 x 6.8 inches at 72 pixels per inch).
Proofs and Reprints
Electronic proofs will be sent as an e-mail attachment to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript and no changes will be made in the manuscript at the proof stage. Authors can freely download the PDF file. Hard copies of the documents are available on request. Please click on the link for the charges.
Copyright
All works published by HILARIS SRL are under the terms of the Creative Commons Attribution License. This permits anyone to copy, distribute, transmit and adapt the work provided the original work and source is appropriately cited.
Cancer Science & Therapy received 3968 citations as per Google Scholar report